본문 바로가기
KERD
논문KCI 등재

COVID-19 Vaccination in Korea

Park Wan Beom|Hwang Young Hoon|Cheong Hee Jin
대한감염학회 (The Korean Society Of Infectious Diseases)|2023.03|Infection and Chemotherapy|제55권 제1호|pp. 135-149|DOI 10.3947/ic.2023.0023

0

조회

0

다운로드

7

인용

0

참고문헌

키워드

COVID-19VaccinationSARS-CoV-2
주제분류내과학

초록

Since December 2020, various coronavirus disease 2019 (COVID-19) vaccines have been developed and approved. As of February 2023, mRNA vaccines including bivalent vaccines (Pfizer/BioNTech, Moderna), recombinant protein vaccines (Novavax, SK Bioscience), and viral vector vaccines (AstraZeneca, Janssen) have been approved in Korea. COVID-19 vaccination can effectively reduce hospitalization and deaths due to symptomatic COVID-19, especially severe and critical COVID-19. The primary series vaccination against COVID-19 is recommended for all adults aged ≥18 years in Korea. Booster vaccination with the bivalent mRNA vaccine is available for those ≥12 years who have completed the primary series vaccination, regardless of the type of vaccine previously received, and is recommended for all adults. Booster vaccination can be administered since 90 days after the last dose. Localized and systemic adverse events following COVID-19 vaccination are relatively common and more frequently documented in younger age groups. Rare but potentially serious specialized adverse reactions include anaphylaxis, thrombosis with thrombocytopenia syndrome, myocarditis, and Guillain-Barré syndrome. Previous severe allergic reactions, such as anaphylaxis, to any COVID19 vaccine or vaccine component are considered a contraindication for vaccination. The indications and schedule for COVID-19 vaccination are subject to change based on further research results and the COVID-19 pandemic.

Abstract

Since December 2020, various coronavirus disease 2019 (COVID-19) vaccines have been developed and approved. As of February 2023, mRNA vaccines including bivalent vaccines (Pfizer/BioNTech, Moderna), recombinant protein vaccines (Novavax, SK Bioscience), and viral vector vaccines (AstraZeneca, Janssen) have been approved in Korea. COVID-19 vaccination can effectively reduce hospitalization and deaths due to symptomatic COVID-19, especially severe and critical COVID-19. The primary series vaccination against COVID-19 is recommended for all adults aged ≥18 years in Korea. Booster vaccination with the bivalent mRNA vaccine is available for those ≥12 years who have completed the primary series vaccination, regardless of the type of vaccine previously received, and is recommended for all adults. Booster vaccination can be administered since 90 days after the last dose. Localized and systemic adverse events following COVID-19 vaccination are relatively common and more frequently documented in younger age groups. Rare but potentially serious specialized adverse reactions include anaphylaxis, thrombosis with thrombocytopenia syndrome, myocarditis, and Guillain-Barré syndrome. Previous severe allergic reactions, such as anaphylaxis, to any COVID19 vaccine or vaccine component are considered a contraindication for vaccination. The indications and schedule for COVID-19 vaccination are subject to change based on further research results and the COVID-19 pandemic.

참고문헌 (70)

  1. Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese center for disease control and prevention", JAMA, 323, pp.1239~1242 (2020)
  2. "WHO coronavirus (COVID-19) dashboard"[URL]
  3. Dai L, "Viral targets for vaccines against COVID-19", Nat Rev Immunol, 21, pp.73~82 (2021)
  4. "COVID-19 vaccine and therapeutic product approval and review"[URL]
  5. "Tracking SARS-CoV-2 variants"[URL]
  6. "Coronavirus disease-19"[URL]
  7. Berlin DA, "Severe Covid-19", N Engl J Med, 383, pp.2451~2460 (2020)
  8. Gandhi RT, "Mild or Moderate Covid-19", N Engl J Med, 383, pp.1757~1766 (2020)
  9. "Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals"[URL]
  10. Hoang Tung, "Comparison of Comorbidities in Relation to Critical Conditions among Coronavirus Disease 2019 Patients: A Network Meta-Analysis", Infection and Chemotherapy, 53(1), pp.13~28 (2021), 대한감염학회[DOI]
  11. 강승지, "Age-Related Morbidity and Mortality among Patients with COVID-19", Infection and Chemotherapy, 52(2), pp.154~164 (2020), 대한감염학회[DOI]
  12. "IDSA guidelines on the treatment and management of patients with COVID-19. Version 10.2.0" (2022)[URL]
  13. Kim Sun Bean, "Revised Korean Society of Infectious Diseases", National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19, 2021, pp.53(1), 166~219[DOI]
  14. "Infectious Diseases Society of America guidelines on infection prevention for healthcare personnel caring for patients with suspected or known COVID-19. Version 2.0.0" (2021)[URL]
  15. Park Sun Hee, "Personal Protective Equipment for Healthcare Workers during the COVID-19 Pandemic", Infection and Chemotherapy, 52(2), pp.165~182 (2020), 대한감염학회[DOI]
  16. Kim Chang Seong, "Nosocomial Outbreak of COVID-19 from a Kidney Transplant Patient: Necessity of a Longer Isolation Period in Immunocompromised Patients", Infection and Chemotherapy, 55(1), pp.42~49 (2023), 대한감염학회[DOI]
  17. "Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States"[URL]
  18. "Strategic advisory group of experts on immunization (SAGE)"[URL]
  19. "COVID-19 vaccines and immunizations"[URL]
  20. Link-Gelles R, "Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection-increasing community access to testing program, United States, September-November 2022", MMWR Morb Mortal Wkly Rep, 71, pp.1526~1530 (2022)
  21. Eyre DW, "Effect of Covid-19 vaccination on transmission of alpha and delta variants", N Engl J Med, 386, pp.744~756 (2022)
  22. Abu-Raddad LJ, "Waning mRNA-1273 vaccine wffectiveness against SARS-CoV-2 infection in Qatar", N Engl J Med, 386, pp.1091~1093 (2022)
  23. Feikin DR, "Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease : results of a systematic review and meta-regression", Lancet, 399, pp.924~944 (2022)
  24. Lamptey Emmanuel, "Should Breakthrough SARS-CoV-2 Infection Affect Our Confidence in the COVID-19 Vaccines?", Infection and Chemotherapy, 53(4), pp.676~685 (2021), 대한감염학회[DOI]
  25. Levin EG, "Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months", N Engl J Med, 385, pp.e84~ (2021)
  26. Andrews N, "Covid-19 Vaccine Effectiveness against the Omicron(B. 1. 1. 529)Variant", N Engl J Med, 386, pp.1532~1546 (2022)
  27. Lin DY, "Effectiveness of bivalent boosters against severe omicron infection", N Engl J Med, 388, pp.764~766 (2023)
  28. Surie D, "Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated hospitalization among immunocompetent adults aged ≥65 years-IVY network, 18 states, September 8-November 30, 2022", MMWR Morb Mortal Wkly Rep, 71, pp.1625~1630 (2022)
  29. Frenck RW Jr, "Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents", N Engl J Med, 385, pp.239~250 (2021)
  30. Muñoz FM, "Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age", N Engl J Med, 388, pp.621~634 (2023)
  31. Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
  32. Thomas SJ, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months", N Engl J Med, 385, pp.1761~1773 (2021)
  33. Haas EJ, "Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel : an observational study using national surveillance data", Lancet, 397, pp.1819~1829 (2021)
  34. Thompson MG, "Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings", N Engl J Med, 385, pp.1355~1371 (2021)
  35. Bar-On YM, "Protection against Covid-19 by BNT162b2 booster across age groups", N Engl J Med, 385, pp.2421~2430 (2021)
  36. Moreira ED Jr, "C4591031 clinical trial group. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine", N Engl J Med, 386, pp.1910~1921 (2022)
  37. Baden LR, "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine", N Engl J Med, 384, pp.403~416 (2021)
  38. El Sahly HM, "Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase", N Engl J Med, 385, pp.1774~1785 (2021)
  39. Tenforde MW, "Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ≥65 years-United States, January-March 2021", MMWR Morb Mortal Wkly Rep, 70, pp.674~679 (2021)
  40. Tseng HF, "Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants", Nat Med, 28, pp.1063~1071 (2022)
  41. Falsey AR, "Phase 3 safety and efficacy of AZD1222(ChAdOx1 nCoV-19)Covid-19 vaccine", N Engl J Med, 385, pp.2348~2360 (2021)
  42. Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
  43. Voysey M, "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19(AZD1222)vaccine : a pooled analysis of four randomised trials", Lancet, 397, pp.881~891 (2021)
  44. Sadoff J, "Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19", N Engl J Med, 384, pp.2187~2201 (2021)
  45. Hardt K, "Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2. S vaccine against COVID-19(ENSEMBLE2) : results of a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Infect Dis, 22, pp.1703~1715 (2022)
  46. Gray G, "Effectiveness of Ad26. COV2. S and BNT162b2 vaccines against omicron variant in South Africa", N Engl J Med, 386, pp.2243~2245 (2022)
  47. Heath PT, "Safety and efficacy of NVX-CoV2373 covid-19 vaccine", N Engl J Med, 385, pp.1172~1183 (2021)
  48. Shinde V, "Efficacy of NVX-CoV2373 covid-19 vaccine against the B. 1. 351 Variant", N Engl J Med, 384, pp.1899~1909 (2021)
  49. Walls AC, "Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2", Cell, 183, pp.1367~1382 (2020)
  50. Song JY, "Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine(GBP510)adjuvanted with AS03 : A randomised, placebo-controlled, observer-blinded phase 1", 2 trial, 2022, pp.51, 101569~
  52. Chalkias S, "A bivalent omicron-containing booster vaccine against Covid-19", N Engl J Med, 387, pp.1279~1291 (2022)
  53. Winokur P, "Bivalent omicron BA. 1-adapted BNT162b2 booster in adults older than 55 years", N Engl J Med, 388, pp.214~227 (2023)
  54. Nham Eliel, "Vaccination Rates of Hospitalized Patients at High Risk of Severe COVID-19: A Single-Center Cross-Sectional Study", Infection and Chemotherapy, 54(4), pp.787~791 (2022), 대한감염학회[DOI]
  55. Eun Bi Noh, "Which Group Should be Vaccinated First?: A Systematic Review", Infection and Chemotherapy, 53(2), pp.261~270 (2021), 대한감염학회[DOI]
  56. Islam N, "Comparative effectiveness over time of the mRNA-1273(Moderna)vaccine and the BNT162b2(Pfizer-BioNTech)vaccine", Nat Commun, 13, pp.2377~ (2022)
  57. Buchan SA, "Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada", JAMA Netw Open, 5, pp.e2218505~ (2022)
  58. Skowronski DM, "Two-dose severe acute respiratory syndrome coronavirus 2 vaccine effectiveness with mixed schedules and extended dosing intervals : test-negative design studies from British Columbia and Quebec, Canada", Clin Infect Dis, 75, pp.1980~1992 (2022)
  59. Lazarus R, "Safety and immunogenicity of concomitant administration of COVID-19 vaccines(ChAdOx1 or BNT162b2)with seasonal influenza vaccines in adults in the UK(ComFluCOV) : a multicentre, randomised, controlled, phase 4 trial", Lancet, 398, pp.2277~2287 (2021)
  60. Alrashdan Mohammad S., "The Co-Administration of COVID-19 and Hepatitis B Vaccines, Should Safety Be a Concern?", Infection and Chemotherapy, 54(3), pp.542~544 (2022), 대한감염학회[DOI]
  61. Choi Won Suk, "Should the COVID-19 Vaccine be Administered Simultaneously with Other Vaccines?", Infection and Chemotherapy, 53(3), pp.589~591 (2021), 대한감염학회[DOI]
  62. Chapin-Bardales J, "Reactogenicity following receipt of mRNA-based COVID-19 vaccines", JAMA, 325, pp.2201~2202 (2021)
  63. Dunkle LM, "Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico", N Engl J Med, 386, pp.531~543 (2022)
  64. Shay DK, "Safety monitoring of the Janssen(Johnson & Johnson)COVID-19 vaccine-United States, March-April 2021", MMWR Morb Mortal Wkly Rep, 70, pp.680~684 (2021)
  65. Ramasamy MN, "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002) : a single-blind, randomised, controlled, phase 2", 3 trial, 2021, pp.396, 1979~1993
  66. Shimabukuro TT, "Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021", JAMA, 325, pp.1101~1102 (2021)
  67. Klok FA, "Vaccine-induced immune thrombotic thrombocytopenia", Lancet Haematol, 9, pp.e73~80 (2022)
  68. Witberg G, "Myocarditis after Covid-19 vaccination in a large health care organization", N Engl J Med, 385, pp.2132~2139 (2021)
  69. Oster ME, "Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021", JAMA, 327, pp.331~340 (2022)
  70. Truong DT, "Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults : suspected myocarditis after COVID-19 vaccination", Circulation, 145, pp.345~356 (2022)

관련 논문AI추천

코로나바이러스감염증-19 (coronavirus disease 2019) 백신과 이상 반응정은희대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2021 · 제9권 제3호Current Status of COVID-19 Outbreak and Vaccination in the Republic of Korea김명류, 홍복실, Jueun Kwon동북아학술저널연합 · International Journal of Crisis & Safety2021 · 제6권 제3호코로나바이러스 감염증-19 백신에 대한 업데이트 및 소아청소년에서의 고려사항Choi Eun Hwa, Kang Hyun Mi, Kim Yae-Jean대한소아감염학회 · Pediatric Infection and Vaccine2021 · 제28권 제1호COVID-19 Vaccination Recommendations for 2024–2025 in KoreaChoi Jun Yong, Choi Min Joo, Choi Won Suk, Choo Eun Ju, Heo Jung Yeon, Hwang Young Hoon, Kwon Ki Tae, Noh Ji Yun, Park Sun Hee, Park Wan Beom, Song Joon Young대한감염학회 · Infection and Chemotherapy2024 · 제56권 제4호COVID-19 Vaccination Recommendations for 2025–2026 in KoreaChoi Jun Yong, Choi Min Joo, Choi Won Suk, Choo Eun Ju, Heo Jung Yeon, Hwang Young Hoon, Kwon Ki Tae, Noh Ji Yun, Park Sun Hee, Park Wan Beom, Song Joon Young대한감염학회 · Infection and Chemotherapy2025 · 제57권 제4호코로나바이러스 감염증-19 백신 이상반응조은정대한이비인후과학회 부산,울산,경남 지부회 · 임상이비인후과2022 · 제33권 제2호

이 간행물의 다른 논문 (22건)

Gram-Negative Bacteria’s Outer Membrane VesiclesKang Jae Seong, Kim Jeong Yeon, Suh Jin Woong, 윤영경, 손장욱, Kim Sun Beanpp. 1-9Diagnosis and Treatment of Invasive Mold DiseasesLee Sang-Ohpp. 10-21Positron Emission Tomography with Computed Tomography in Evaluations of Classical Fever of Unknown Origin and Length of Hospitalization: A 10-Year Medical Record Review of a Tertiary HospitalBae Sang Woonpp. 22-28Population Pharmacokinetics and Monte Carlo Simulation of Cefepime in Critically Ill Patients with Hospital-Acquired/Ventilator-Associated PneumoniaLee Dong-Hwan, 김용균, Seo Hyeonji, Park Sunghoon, Kim Hwan-ilpp. 29-41Nosocomial Outbreak of COVID-19 from a Kidney Transplant Patient: Necessity of a Longer Isolation Period in Immunocompromised PatientsChoi Okja, Lee Kwangho, 최홍상, Bae Eun Hui, 마성권, 김성은, 김수완, 박경화, 강승지, 정숙인, Lee Yoonjung, Kim Sun-Hee, Chung Yoon-Seok, Kim Uh Jin, Kim Chang Seong, Lee Unheepp. 42-49
원문 보기